Credenceresearch

Fabry Disease Treatment Market   size was valued at USD 2474.5 million in 2024 and is anticipated to reach USD 4186.19 million by 2032, at a CAGR of 7.8% during the forecast period.   Fabry disease is a rare genetic lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A (α-Gal A), leading to the accumulation of globotriaosylceramide (GL-3) and related lipids in various tissues. This buildup results in a range of systemic complications affecting the kidneys, heart, and nervous system. As research advances and awareness grows, the Fabry disease treatment market is witnessing significant developments driven by innovation in enzyme replacement therapy (ERT), gene therapy, and pharmacological chaperones. Browse the full report at:  https://www.credenceresearch.com/report/fabry-disease-therapeutic-market Market Overview The global Fabry disease treatment market has experienced notable growth in recent years due to advancements in precision medicin...